Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.56
+0.19 (2.98%)
At close: Jun 26, 2026, 4:00 PM EDT
6.50
-0.06 (-0.91%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Profound Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Profound Medical stock have an average target of 11, with a low estimate of 10 and a high estimate of 12. The average target predicts an increase of 67.68% from the current stock price of 6.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 18, 2026.
Analyst Ratings
The average analyst rating for Profound Medical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Buy Reiterates $12 | Buy | Reiterates | $12 | +82.93% | May 18, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $12 → $10 | Buy | Reiterates | $12 → $10 | +52.44% | May 8, 2026 |
Financial Forecast
Revenue This Year
26.08M
from 16.10M
Increased by 61.99%
Revenue Next Year
44.25M
from 26.08M
Increased by 69.69%
EPS This Year
-0.85
from -1.41
EPS Next Year
-0.75
from -0.85
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 29.5M | 47.7M | |
| Avg | 26.1M | 44.3M | |
| Low | 24.9M | 42.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 83.4% | 82.8% | |
| Avg | 62.0% | 69.7% | |
| Low | 54.4% | 63.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.85 | -0.75 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.